|

Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer

RECRUITINGN/ASponsored by Samsung Medical Center
Actively Recruiting
PhaseN/A
SponsorSamsung Medical Center
Started2022-11-01
Est. completion2031-12-31
Eligibility
Age20 Years – 80 Years
SexFEMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05876130

Summary

To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.

Eligibility

Age: 20 Years – 80 YearsSex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* histologically confirmed endometrioid type endometrial cancer
* completion of hysterectomy and surgical staging
* pathologically confirmed FIGO stage III
* ECOG performance status 0 or 1
* adjuvant chemotherapy was done or planned

Exclusion Criteria:

* presence of distant metastasis
* previous history of pelvic radiotherapy
* severe and unstable medical condition
* previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer

Conditions2

CancerEndometrial Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.